Drug intelligence / Profile preview

thbs2 siRNA

Development stage
Preclinical
Lead developer
MedChemExpress
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Subcutaneous, Intravenous
01

Overview

THBS2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the Thrombospondin-2 (THBS2) gene. THBS2 is a secreted glycoprotein involved in cell-matrix interactions and has been identified as a key driver of inflammation and fibrogenic remodeling in metabolic dysfunction-associated steatohepatitis (MASH) and various cancers. By targeting THBS2 mRNA for degradation, this siRNA reduces THBS2 protein levels, thereby inhibiting the activation of macrophages and hepatic stellate cells via integrin alpha 5 signaling. While primarily used as a research tool, hepatocyte-targeted versions (e.g., GalNAc-conjugated) are being explored in preclinical models for the treatment of MASH and liver fibrosis.

Other names
Thbs2 siRNAThbs-2 siRNAThbs 2 siRNAThrombospondin-2 siRNAThrombospondin2 siRNAThrombospondin 2 siRNAGalNAc-conjugated Thbs2 siRNA
02

Targets

Thrombospondin 2 mRNA

Beyond the preview

Go deeper on thbs2 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on thbs2 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call